assay · intermediate · partly written
Selectivity panel
A set of related or liability proteins a compound is tested against, to see what else it hits.
Also called: kinase panel, safety panel, off-target panel, counter-screen panel
Question answered
Besides the target, which of the proteins on this list does the compound bind or inhibit, and how much more weakly? Kinase panels test purified kinases; in vitro safety panels test a chosen list of liability targets (receptors, channels, enzymes) that companies have linked to adverse effects. 12
Reported, not yet replicated
Readout physical
Not measured
Anything not on the list: proteins outside the family, activity in cells, and toxicity. One analysis of panel data concludes that small assay panels do not provide a robust measure of selectivity (abstract). Whether safety-panel hits predict clinical events was not found. A binding panel also says nothing about how long the drug stays bound, which is the separate idea of kinetic selectivity. 324
Reported, not yet replicated
Setting
Where in cascade
Use cases
ML281 against 83 kinases (Broad probe programme)
At 1 uM against a panel of 83 kinases, only FLT3 and KDR were inhibited 25% or more besides STK33; selectivity over PKA and Aurora B was also measured. 5
Reported, not yet replicated
Kinase inhibitor selectivity at scale
A 2011 study profiled 72 inhibitors against 442 kinases and found that selectivity varies by class and that selective inhibitors exist for most kinases tried. A 2017 study of 243 clinical kinase drugs found polypharmacology is commonly observed, including non-kinase targets. Abstracts read. 16
Reported, not yet replicated
When the panel is not enough
Ten cancer drugs against six proteins still killed cells after CRISPR deletion of the supposed target, so they act through other targets; the drug-indication pairs concerned were in at least 29 trials. An oncology study of a small number of drugs. 7
Reported, not yet replicated
ML role
Does
No machine-learning method specific to selectivity panels was found in the sources opened. 3
Unverified: from our own report, source not opened
Cannot
A model trained on panel data inherits the panel's blind spots: it only knows the proteins that were on the list. 3
Our inference
Still open here
- Cost per compound and turnaround were not found for any panel; no price is written.
- Chemical proteomics (capturing targets from lysate) is the usual complement to a panel; the chain found no source for its limits.
- Throughput class and panel sizes of safety panels were not read beyond abstracts.
Not yet written: Sample prep, Conditions, Throughput class, Throughput, Time per run, Cost, Engineerable variants, Before after, Capital, Emerging, Data availability.
Linked from
Sources
- Davis, Mindy I, Hunt, Jeremy P, Herrgard, Sanna, et al.. Comprehensive analysis of kinase inhibitor selectivity. Nature Biotechnology (2011). paper; opened 2026-11-17 all records citing this
- Bowes, Joanne, Brown, Andrew J., Hamon, Jacques, et al.. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nature Reviews Drug Discovery (2012). paper; opened 2026-11-17 all records citing this
- Karaman, Mazen W, Herrgard, Sanna, Treiber, Daniel K, et al.. A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnology (2008). paper; opened 2026-11-17 all records citing this
- Copeland, Robert A., Pompliano, David L., Meek, Thomas D.. Drug–target residence time and its implications for lead optimization. Nature Reviews Drug Discovery (2006). paper; opened 2026-11-17 all records citing this
- Weiwer et al.. Weiwer et al. 2012: the STK33 probe ML281 (PMC full text). PubMed Central (2012). paper; opened 2026-11-17 all records citing this
- Klaeger, Susan, Heinzlmeir, Stephanie, Wilhelm, Mathias, et al.. The target landscape of clinical kinase drugs. Science (2017). paper; opened 2026-11-17 all records citing this
- Lin, Ann, Giuliano, Christopher J., Palladino, Ann, et al.. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Science Translational Medicine (2019). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (1)
This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/assays/selectivity-panel.json